A Mutant Type 2 Herpes Simplex Virus Deleted for the Protein Kinase Domain of the ICP10 Gene Is a Potent Oncolytic Virus
Open Access
- 1 May 2006
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 13 (5), 882-890
- https://doi.org/10.1016/j.ymthe.2006.02.007
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Viral Shedding and Biodistribution of G207, a MuItimutated, Conditionally Replicating Herpes Simplex Virus Type 1, after Intracerebral Inoculation in AotusMolecular Therapy, 2000
- Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant gliomaGene Therapy, 2000
- Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trialGene Therapy, 2000
- Gene Therapy for Gliomas: Molecular Targets, Adenoviral Vectors, and Oncolytic AdenovirusesExperimental Cell Research, 1999
- Act locally, think globallyNature Medicine, 1997
- Will a Twist of Viral Fate Lead to a New Cancer Treatment?Science, 1996
- The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors.Proceedings of the National Academy of Sciences, 1996
- Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomasNature Medicine, 1995
- Treatment of Experimental Intracranial Murine Melanoma with a Neuroattenuated Herpes Simplex Virus 1 MutantVirology, 1995
- Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus MutantScience, 1991